Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Business Development & Licensing

As what used to be healthcare’s busiest meetings week is going to be a week of virtual interaction around the globe, we thought it worthwhile to share a few considerations on partnering between biotech and large pharma from the perspective of the developing biotech...
An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed...
In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.In late spring when apple trees are filled with young fruits, the best way to ensure a healthy harvest in autumn is to thin out the fruits, which in turn strengthens the tree and helps the remaining fruits grow and ripen.While the gardener knows that the autumn harvest will be stronger for doing it, the thinning out process is painful every time...
Chinese biotech's advance has been as ferocious as the nation's breakthrough efforts in AI and EVs, eclipsing the EU and catching up to the US...
Companies are being asked to take-on increasingly complex challenges in an environment where there are diminished resources...
Mandy Jackson, US editor of Citeline's Scrip, has published the below interview with Ali Pashazadeh, Treehill Partners CEO...
At this year's BIO Convention in Boston, Ali Pashazadeh, Treehill Partners CEO, spoke with Manasee Kurlekar, BioSpectrum Asia Chief Executive Officer...
For most emerging bio-pharma or medtech companies, establishing a development or commercialization partnership is a core component of their strategic plan, and, sealing the deal is cause for much celebration. While hard work and a number of all-nighters may go into signing an agreement, ensuring the partnership achieves its objectives and sails across the finish line is often harder, and often a bumpy ride...
At PCMG Clinical Outsourcing Community today, Ali Pashazadeh, Treehill Partners CEO, was giving a podium presentation on "A view from the top - how will Clinical Development Outsourcing adapt to a rapidly changing landscape"...
Whilst outsourcing of drug development and manufacturing is an attempt to undertake purposeful action in a web of interdependent contingencies, this interview with Ali Pashazadeh, Treehill Partners CEO...
Outsourced Pharma Chief Editor Louis Garguilo has interviewed Ali Pashazadeh, Treehill Partners CEO, to help think through the evolving U.S. policies and tariff turbulance as they relate to the outsourcing of development and manufacturing...
The Pink Sheet and Citeline have just published their summary article 'Quotable: Top Experts on Policy Hot Topics’, picking out 12 recent articles that are ‘must read’....
The majority of pharma and biotech venture creations are aimed at one or both of two fundamental objectives, bringing a novel therapeutic to patients and generating returns for their founders and investors. Often, pathways are poorly understood by the bootstrap team, and professional “help” is being sought from incubators, boards, investors and advisors, embedding possibly conflicting perspectives and goals into the core fabric of the company.